Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT00400374
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
- Conditions
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 8067
- Registration Number
- NCT00373685
- Locations
- 🇵🇷
Pfizer Investigational Site, Trujillo Alto, Puerto Rico
Celebrex Total Knee Arthroplasty Study
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 22
- Registration Number
- NCT00359151
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
- Conditions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 24
- Registration Number
- NCT00357617
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 101
- Registration Number
- NCT00357500
- Locations
- 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 86
- Registration Number
- NCT00355576
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸UMDNJ, New Brunswick, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2012-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00346801
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
- Conditions
- Interventions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 24081
- Registration Number
- NCT00346216
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸AnMed Health, Anderson, South Carolina, United States
🇺🇸Wagdy W. Kades, MD, Inc., Los Angeles, California, United States
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00336960
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus, Nashville, Tennessee, United States
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00305643
- Locations
- 🇺🇸
Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.